Current Multiple Myeloma News and Events

Current Multiple Myeloma News and Events, Multiple Myeloma News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 24 | 954 Results
New recommendations aim to eliminate racial bias in myeloma trials
Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites. (2021-02-18)

Metabolic response behind reduced cancer cell growth
Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells' metabolism. These changes can be used as markers to discriminate whether a patient would respond to treatment by EZH2 inhibition. The study has been published in the journal Cell Death & Disease. (2021-02-12)

Medication-based starvation of cancer cells
Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide have significantly improved the therapy of hematologic malignancies such as multiple myeloma. Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action in this class of medications. At the same time, they identified new innovative targeted cancer therapies. (2021-02-12)

Glitch in genome architecture may cause B-cell malignancies
Restoring an enzyme that maintains the way chromosomes are packed inside cells may lead to new therapies for some blood cancers, according to a new study by Columbia researchers. (2021-02-01)

Two anti-viral enzymes transform pre-leukemia stem cells into leukemia
Viral infections and space travel similarly trigger inflammation and the enzymes APOBEC3C and ADAR1; UC San Diego researchers are developing ways to inhibit them as a means to potentially lower cancer risk for both astronauts and people on Earth. (2021-01-26)

In preclinical models, antiviral better inhibits COVID-19 than Remdesivir; further studies warranted
Working in preclinical models, researchers report that plitidepsin, a drug with limited clinical approval for the treatment of multiple myeloma, is more potent against SARS-CoV-2 than remdesivir, an antiviral that received FDA emergency use authorization for the treatment of COVID-19 in 2020. (2021-01-25)

Whole body imaging detects myeloma in more patients, treatment initiated earlier
Researchers from King's College London have shown that whole body magnetic resonance imaging (WBMRI) not only detects more myeloma-defining disease than positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) but that it also allows critical treatment to be initiated earlier. (2021-01-21)

Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma. (2021-01-20)

Treating an autoimmune disease in mice with an mRNA vaccine
Christina Krienke and colleagues have designed an mRNA vaccine that delayed the onset of and reduced the severity of multiple sclerosis-like disease in mice. (2021-01-07)

Researchers determine how often cancer patients develop osteonecrosis of the jaw
A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone. (2020-12-17)

CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments. (2020-12-06)

ASH: Off-the-shelf immune drug shows promise in aggressive multiple myeloma
A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma. (2020-12-05)

Racial/ethnic minorities comprise small portion of patients referred with AL amyloidosis
Despite being theoretically at an increased risk for AL amyloidosis, underrepresented minorities make up only a small percentage of patients seen at specialized treatment centers for this disease. (2020-11-10)

Penn Study supports use of radiation before CAR therapy for multiple myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy. (2020-10-26)

Anticancer compounds for B cell cancer therapy targeting cellular stress response
Wistar and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (2020-10-13)

Nanoparticles can turn off genes in bone marrow cells
Using specialized nanoparticles, MIT engineers have developed a way to turn off specific genes in cells of the bone marrow, which play an important role in producing blood cells. (2020-10-05)

Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in in patients with large B-cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to treatment and develop side effects. (2020-10-05)

Hackensack Meridian CDI scientists find one-two punch for preclinical cancer models
Research findings published Aug. 14, 2020 in the journal Cancer Research suggest that since some cancer treatments can be undermined by epigenetic changes (altered DNA methylation affecting gene expression) in cancer cells before the treatments are even administered, a worthwhile strategy is to administer an epigenetically-acting drug - which can pave the way for more effective subsequent use of immune-acting cancer treatments. (2020-09-30)

New insights into how the drug pomalidomide fights cancer
Scientists from the Tokyo Institute of Technology, Tokyo Medical University, and Saitama Medical University have published findings that offer insights into how the drug pomalidomide benefits some patients with a cancer called multiple myeloma. Clinicians use pomalidomide to treat cases of multiple myeloma resistant to the more established drug lenalidomide, and the research team found that pomalidomide works by targeting a protein called ARID2. These findings may lead to new treatments for lenalidomide-resistant multiple myeloma. (2020-09-21)

Novel immune-oncology approach for potential cancer treatment
A research collaboration between Monash University and Lava Therapeutics details a novel immune-oncology approach for the potential treatment of cancer. (2020-09-14)

Study finds cancer mapping may solve puzzle of regional disease links
New statistical analysis finds cancer mapping may help question regional disease links. (2020-08-13)

New multiple myeloma therapy shows promise in preclinical study
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine. Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment. (2020-08-06)

Chemists build natural anti-cancer compound with lean new process
Creative chemists employ enzymes to build a complex but promising natural anti-cancer agent called cepafungin I in a lean nine steps. (2020-08-06)

A safer cell therapy harnesses patient T cells to fight multiple myeloma
A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease. (2020-07-29)

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers. (2020-07-09)

Mapping the immune landscape of haematological cancers may help to enhance therapies
Activating the immune system of the body is a promising form of treatment for cancer. Researchers at the University of Helsinki and Helsinki University Hospital as well as the University of Eastern Finland mapped out the immune landscape of haematological malignancies in a dataset covering more than 10,000 patients to identify drug targets and patient groups which could potentially benefit from immunotherapies. (2020-07-09)

Hackensack Meridian CDI scientists uncover signposts in DNA for cancer, disease risk
The most strongly disease-relevant genetic variants can be hard to localize in widespread scanning of the genome -- but by zooming in on key genetic locations associated with DNA methylation imbalances in multiple normal and cancer tissues, the scientists report they have uncovered promising new leads beneath the broader statistical signals. (2020-06-29)

Study documents the challenges of herbicide-resistant annual bluegrass in turf
In an study featured in the journal Weed Science, researchers in Australia examined 31 populations of annual bluegrass suspected to be herbicide resistant. All 31 were found to be resistant to multiple turf herbicides. Three populations had evolved resistance to herbicides with five different mechanisms of action. (2020-06-05)

Colorado tool, My-DST, may pick best multiple myeloma treatment
Response of liquid biopsies to approved drugs can help show resistance, predict response. (2020-05-28)

Carfilzomib does not improve outcomes in newly diagnosed myeloma compared to bortezomib
The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not improve progression-free survival in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care -- bortezomib, lenalidomide, and dexamethasone (VRd). The data from a planned interim analysis for the ENDURANCE (E1A11) randomized phase three trial will be presented at the ASCO 2020 plenary. KRd had more severe cardiac, pulmonary, and renal toxicities. Neuropathy was more common among those receiving VRd. (2020-05-28)

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity. (2020-05-18)

SWOG researchers go digital at ASCO20 Virtual Scientific Program
Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31. (2020-05-18)

ECOG-ACRIN research at ASCO 2020
Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of research findings at the annual meeting of the American Society of Clinical Oncology (ASCO), occurring virtually May 29-31. The presentations include late-breaking data in two plenary sessions and several oral abstract presentations. National Cancer Institute, part of the National Institutes of Health, funded these studies. (2020-05-13)

Immune system changes occur early in development of multiple myeloma, study finds
Long before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergoes dramatic shifts, with alterations in both the number and type of immune cells, researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital (MGH) report in a new study. (2020-04-27)

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report, published in Blood Advances, also suggests that blood cancer patients may have atypical COVID-19 symptoms. (2020-04-03)

Blood test accurately detects over 50 types of cancer, often before symptoms show
Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated, often before there are any signs of the disease. The test has a false positive rate of less than 1% meaning that less than 1% of people would be wrongly identified as having cancer. It can correctly predict the tissue in which the cancer originated in 93% of samples. The study is published in Annals of Oncology. (2020-03-30)

Blood test detects wide range of cancers, available to at risk individuals in clinical study
In a study involving thousands of participants, a new blood test detected more than 50 types of cancer as well as their location within the body with a high degree of accuracy, according to an international team of researchers led by Dana-Farber Cancer Institute. (2020-03-30)

New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options. These promising results could pave the way for the new drug to be tested in patients. (2020-03-27)

New technology helps in hunt for new cancer drug combinations
A revolutionary new technology has been applied to reveal the inner workings of individual cancer cells - potentially identifying more effective treatment combinations for people with cancer. (2020-03-19)

Genetic test could pick out 'ultra high risk' bone marrow cancer patients
A new genetic test could help doctors pick out patients with the bone marrow cancer multiple myeloma who are at 'ultra high risk' of their cancer progressing aggressively early on. (2020-03-10)

Page 1 of 24 | 954 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.